Qualigen Therapeutics presents scientific data on QN-302 at AACR conference

Qualigen Therapeutics announces the presentation of two posters on the Company’s lead compound, QN-302, at the ninth American Academy of Cancer Research, AACR, Special Conference on Pancreatic Cancer held September 27th to 30th at the Westin Copley Place in Boston. “The data from these two posters demonstrate information that is instrumental in understanding the importance of QN-302, a G-Quadruplex targeted transcription inhibitor and its potential profile in Pancreatic Cancer,” commented Tariq Arshad, M.D., M.B.A., Qualigen’s Chief Medical Officer. “The inclusion of these data at the AACR Pancreatic Cancer Research meeting provides further elucidation of our therapeutic approach in treating this devastating disease. We are delighted that QN-302’s Investigational New Drug application was cleared by FDA and QN-302 is on track to enter the clinic this year.”